Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congressional Oversight “Misunderstood” By Von Eschenbach – Grassley

This article was originally published in The Tan Sheet

Executive Summary

Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened

You may also be interested in...



Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch

One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight

Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch

One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight

Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch

One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel